{"id":12556,"date":"2022-11-04T17:07:05","date_gmt":"2022-11-04T11:37:05","guid":{"rendered":"https:\/\/univest.in\/blogs\/?p=12556"},"modified":"2022-11-04T17:07:05","modified_gmt":"2022-11-04T11:37:05","slug":"sun-pharma-results-q2fy23","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-results-q2fy23\/","title":{"rendered":"Sun Pharma results Q2FY23"},"content":{"rendered":"

Sun is the world\u2019s fourth largest generics\/specialty pharma company with 43 manufacturing sites at its disposal addressing segments like specialty products, branded generics, complex generics, pure generics, and APIs. With a market share of 8.6%, Sun is ranked No. 1 in domestic formulations. It enjoys a leadership position in 11 specialties based on prescription and has a market cap of Rs 2,46,412 crores. The company on 1st November\u201922 announced their Q2FY23 results, where they reported better-than-expected Q2 numbers. This robust performance was led by superior execution in the Specialty portfolio, US Generics (excluding Taro), and the Domestic Formulation (DF) segment; benefits from the PLI scheme; and a favourable currency movement. Even on the stock market, the stock price has gone up and is currently trading close to its 52 weeks high. So, let\u2019s now have a look at the company\u2019s Q2FY23 and check whether there is any hidden investment opportunity.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n